KRAS and Cirrhosis: Eight of the 18 (44.4%) patients who relapsed had cirrhosis (5 received 12 weeks of simeprevir treatment; 3 received ≥24 weeks of simeprevir treatment), 6 of 18 (33.3%) were treatment-experienced, 11 of 18 (61.1%) had HCV genotype/subtype 1a (neither of the 2 patients with available data had the NS3 Q80K polymorphism), and 6 of 18 (33.3%) had genotype/subtype 1b (genotype/subtype was indeterminate for 1 patient).